title: Your critical care patient may have HLH (hemophagocytic lymphohistiocytosis).
authors.affiliation: Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, ul. Banacha 1a, 02-097, Warsaw, Poland. r.machowicz@wp.pl.
authors.forename: Rafal
authors.initials: R
authors.lastname: Machowicz
authors.affiliation: Department of Paediatric Haematology and Oncology, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
authors.forename: Gritta
authors.initials: G
authors.lastname: Janka
authors.affiliation: Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, ul. Banacha 1a, 02-097, Warsaw, Poland.
authors.forename: Wieslaw
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
mesh_terms: D016638:Critical Illness; D003937:Diagnosis, Differential; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007362:Intensive Care Units / Q000458:organization & administration; D007501:Iron / Q000032:analysis / Q000097:blood; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D059005:Topoisomerase II Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D059005:Topoisomerase II Inhibitors; D005047:Etoposide; D007501:Iron